Neuromelanin Magnetic Resonance Imaging of the Substatia Nigra in LRRK2 -related Parkinson’s disease
Objective: Our study aimed to evaluate neuromelanin-Magnetic Resonance signal changes in PD patients carrying a LRRK2 mutation. Background: Specific magnetic resonance (MR) sequences are able to…Data driven analysis for exploring phenotypic differences in patients with Parkinson’s disease with or without genetic mutations.
Objective: To explore, using a data driven statistical analysis method, discriminating phenotype features of disease in a large group of patients with Parkinson’s disease (PD)…Gene associated differences in pre-diagnostic symptoms of Parkinson’s Disease: a retrospective study
Objective: To investigate whether glucocerebrosidase (GBA) L444P and leucine-rich repeat kinase 2 (LRRK2) G2385R and R1628P mutations are associated with different symptoms and manifesting patterns…Motor and Nonmotor clinical phenotype in LRRK2 Parkinson’s disease patients: a Case-control study
Objective: Our study aimed to characterize and compare the clinical phenotype of LRRK2-PD patients with PD patients with no identified mutations. Background: The clinical phenotype…Altered intrinsic brain functional connectivity in drug-naïve Parkinson’s disease with LRRK2 mutation
Objective: This study aimed to compare the alterations in the cortico-striatal functional connectivity (FC) of drug-naïve Parkinson’s disease (PD) patients with the leucine-rich repeat kinase…Detection of leucine-rich repeat kinase 2 in human biofluids
Objective: To evaluate the presence of leucine-rich repeat kinase 2 (LRRK2) in human biosamples, including cerebrospinal fluid (CSF) and urine, as a first step towards…A cognitive fMRI study of non-manifesting LRRK2 and GBA carriers
Objective: To assess the cognitive profile of non-manifesting carriers of GBA and LRRK2 mutations using two fMRI tasks: a Stroop interference and N-Back working memory…Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity
Objective: To identify disease-modifying therapy for LRRK2-G2019S parkinsonism. Background: Leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of Parkinson's disease (PD) without…Lack of association between LRRK2 G2385R and cognitive dysfunction in Korean patients with idiopathic Parkinson’s disease
Objective: We investigated whether the G2385R polymorphism in LRRK2, a risk allele for the development of idiopathic Parkinson's disease (IPD) in East Asians, is associated…Reduced thalamo-cortical functional connectivity in asymptomatic LRRK2 mutation carriers
Objective: To characterize MRI functional patterns during resting state in asymptomatic LRRK2 mutation carriers. Background: Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.